Veeva and BioMarin Form Long-Term Strategic Partnership
Rhea-AI Summary
BioMarin (NASDAQ: BMRN) and Veeva Systems (NYSE: VEEV) announced a long-term enterprise agreement on January 8, 2026 to expand their existing relationship.
The partnership aims to increase speed, agility and operational efficiency in developing and commercializing therapies by further leveraging and providing strategic input into Veeva's software, data, services, and consulting products, and to optimize the healthcare professional and patient experience. Company leaders highlighted the collaboration's role in accelerating access to transformative medicines globally.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, BMRN declined 1.57%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
BMRN was up 2.06% while close peers like BBIO, IONS, EXEL, ASND, and SMMT showed modest gains but did not appear in momentum scans, suggesting today’s move is more company-specific than a broad biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 19 | Strategic acquisition | Positive | +17.7% | All-cash Amicus deal to expand rare disease portfolio and revenues. |
| Nov 11 | Conference participation | Neutral | +4.3% | Jefferies conference presentation and webcast access details for investors. |
| Oct 29 | Regulatory update | Positive | -3.0% | FDA Priority Review for PALYNZIQ label expansion in adolescents with PKU. |
| Oct 29 | Earnings results | Negative | -3.3% | Q3 2025 revenue growth but GAAP loss and lower Non-GAAP guidance. |
| Oct 22 | Earnings call notice | Neutral | +2.2% | Announcement of Q3 2025 earnings call and webcast logistics. |
Recent news reactions mostly aligned with event tone, except a positive clinical/regulatory update that saw a negative price reaction.
Over the past few months, BioMarin has reported a mix of strategic, clinical, and financial developments. On Oct 27, 2025, Q3 results showed revenue growth but included a GAAP loss and lower Non-GAAP guidance, prompting a negative reaction. A few days later, on Oct 29, 2025, the FDA’s Priority Review acceptance for PALYNZIQ was positive but met with a price decline. Subsequent conference participation and the announced $4.8 billion Amicus acquisition on Dec 19, 2025 drew positive moves. Today’s long-term partnership with Veeva fits into this pattern of strategic positioning to support pipeline and commercialization.
Market Pulse Summary
This announcement highlights a long-term enterprise partnership between BioMarin and Veeva aimed at improving speed, agility, and operational efficiency in developing and commercializing therapies. It reinforces BioMarin’s emphasis on digital capabilities to support its rare-disease portfolio following recent clinical, earnings, and acquisition updates. Investors may watch how this collaboration translates into execution benefits, such as faster development timelines or improved commercial reach, alongside the integration of recently acquired assets and ongoing regulatory milestones.
AI-generated analysis. Not financial advice.
Partnership to help BioMarin increase speed and efficiency
in developing and commercializing innovative therapies
The expanded partnership will help BioMarin increase speed, agility, operational efficiency, and optimize the healthcare professional and patient experience by further leveraging and providing strategic input into Veeva's software, data, services, and consulting products.
"This strategic partnership marks an important next step in our digital evolution," said Alexander Hardy, President and Chief Executive Officer of BioMarin. "We are excited by the opportunity to combine our scientific capabilities with Veeva's technological leadership that we believe will enable us to bring our transformative medicines more quickly to patients around the world."
"Our partnership with BioMarin has always been guided by a shared set of values, including product excellence, value realization, and customer success," said Veeva CEO Peter Gassner. "Building on this foundation, I look forward to how we can further support BioMarin as they advance important new medicines and reach even more patients around the world."
About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the
About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
BioMarin Forward-Looking Statements
This release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: BioMarin's expectations regarding Veeva's products and services and the expected results or benefits from BioMarin's use of Veeva's products and services. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the success of the strategic partnership between BioMarin and Veeva, BioMarin's ability to utilize Veeva's products and services to bring BioMarin's medicines more quickly to patients, and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended October 31, 2025, as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioMarin®, is a registered trademark of BioMarin Pharmaceutical Inc.
Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.
Contact: | |
Maria Scurry | |
Veeva Systems | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/veeva-and-biomarin-form-long-term-strategic-partnership-302656052.html
SOURCE Veeva Systems
FAQ
What did BioMarin (BMRN) announce with Veeva on January 8, 2026?
How will the Veeva partnership affect BioMarin's drug development timelines?
Which Veeva products will BioMarin use under the new BMRN agreement?
Does the BioMarin and Veeva deal on January 8, 2026 include financial terms or timelines?
What is the strategic goal of BioMarin's expanded partnership with Veeva (BMRN)?
